<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862599</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1512</article-id><article-id pub-id-type="other">EPV0913</article-id><article-id pub-id-type="pii">S0924933824015128</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Initiation of Paliperidone palmitate 3-monthly injectable in an acute inpatient psychiatric unit</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pareja Zea</surname><given-names>A. S.</given-names></name><xref rid="aff3311" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1361" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vera-Varela</surname><given-names>C.</given-names></name><xref rid="aff3311" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez Mart&#x000ed;nez</surname><given-names>A.</given-names></name><xref rid="aff3312" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a Jimenez</surname><given-names>G.</given-names></name><xref rid="aff3311" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Iceta Iba&#x000f1;ez de Gauna</surname><given-names>M.</given-names></name><xref rid="aff3311" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff3311"><sup>1</sup>Psychiatry</aff><aff id="aff3312"><sup>2</sup>Pharmacy, <institution>Infanta Sofia University Hospital</institution>, <city>Madrid</city>, <country>Spain</country></aff><author-notes><corresp id="cor1361"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1487">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S727</fpage><lpage>S727</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015128a.pdf"/><abstract><sec id="sec8182"><title>Introduction</title><p>
The treatment of patients with severe psychotic disorders presents significant clinical challenges, and the choice of appropriate therapy is essential to ensure long-term stability<sup>1</sup>. In this context, long-acting injectable antipsychotics (LAIs) have emerged as a promising therapeutic option. LAIs were developed to counteract poor treatment adherence in patients with psychotic disorders<sup>2</sup>.</p><p>Paliperidone palmitate 3-monthly injectable (PP3M) is a novel formulation of intramuscular injectable paliperidone palmitate with a significantly longer half-life than the once-monthly formulation.</p><p>PP3M has shown a longer time to relapse and good safety and tolerability in many studies<sup>3</sup>.</p></sec><sec id="sec8183"><title>Objectives</title><p>The aim of this work was to describe the profile of patients initiating PP3M in an acute inpatient psychiatric unit.</p></sec><sec id="sec8184"><title>Methods</title><p>
A descriptive study was conducted on patients admitted to the acute psychiatric unit from January 2021 to December 2022. The sample included 23 inpatients who initiated PP3M during the admission. Data were collected regarding age, gender, diagnosis, substance abuse, previous antipsychotic treatment, antipsychotic treatment adherence and adverse effects during the admission.</p></sec><sec id="sec8185"><title>Results</title><p>23 patients sample, with an average age of 44.04 years-old, 16 male and 7 female, diagnosed with psychotic disorder (22) and schizoaffective disorder (1). Out of the 23 patients, 7 had active substance abuse upon admission.</p><p>
Out of the total simple, 9 of them were prescribed LAIs, with 6 on PP1M (Paliperidone palmitate 1-monthly injectable), 2 on PP3M, and 1 on aripiprazole long-acting injection. Twelve were prescribed oral antipsychotics, including 4 on paliperidone, 4 on risperidone, 1 on aripiprazole, 1 on olanzapine, and 2 on other oral antipsychotics. Two patients did not have a previous antipsychotic prescription.</p><p>Among the 23 patients, 17 of them did not have previous antipsychotic treatment adherence.</p><p>5 out of the 23 patients experienced adverse effects, with 3 of them having extrapyramidal symptoms and 2 hyperprolactinemia.Upon discharge, 11 out of the 23 patients were prescribed antipsychotic monotherapy with PP3M.</p></sec><sec id="sec8186"><title>Conclusions</title><p>In this sample, we observed that inpatients who initiated PP3M in an acute psychiatric unit were males, with psychotic disorders, lacked adherence to previous antipsychotic treatment. Most of them did not experience adverse effects with PP3M during admission.</p><p>More research should be done to assess the use of&#x000a0;PP3M in an acute inpatient psychiatric unit.</p><p>REFERENCES</p><p>1. Morris MT, Tarpada SP. Psychopharmacol Bull. 2017 May 15;47(2):42-52.</p><p>2. Brasso, C., Bellino, S., Bozzatello, P., Montemagni, C., &#x00026; Rocca, P. (2017). Neuropsychiatric Disease and Treatment,</p><p>3. Edinoff AN, Doppalapudi PK, Orellana C, Ochoa C, Patti S, Ghaffar Y, Cornett EM, Kaye AJ, Viswanath O, Urits I, Kaye AM, Kaye AD. Front Psychiatry. 2021.</p></sec><sec id="sec8187"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>